TCGA-D8-A1JS-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.620
- FATTY_ACID_METABOLISM+0.430
- DNA_REPAIR+0.360
- ESTROGEN_RESPONSE_EARLY+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.300
- ADIPOGENESIS+0.280
- ESTROGEN_RESPONSE_LATE+0.280
- PANCREAS_BETA_CELLS+0.280
- MYC_TARGETS_V1+0.250
- MYC_TARGETS_V2+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- MITOTIC_SPINDLE-0.510
- G2M_CHECKPOINT-0.480
- ALLOGRAFT_REJECTION-0.450
- INFLAMMATORY_RESPONSE-0.440
- HEDGEHOG_SIGNALING-0.420
- KRAS_SIGNALING_UP-0.420
- TNFA_SIGNALING_VIA_NFKB-0.420
- IL2_STAT5_SIGNALING-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A133-01A-32R-A12D-07 | — | B | 0.893 |
| 2 | TCGA-B6-A0RO-01A-22R-A084-07 | — | C | 0.884 |
| 3 | TCGA-TN-A7HJ-01A-12R-A34R-07 | — | — | 0.877 |
| 4 | TCGA-BH-A18S-01A-11R-A12D-07 | — | B | 0.875 |
| 5 | SRR8518211 | — | C | 0.871 |
| 6 | C3N-02153 | — | cohortA1 | 0.865 |
| 7 | MNG1094 | — | — | 0.860 |
| 8 | SRR8518413 | — | F | 0.851 |
| 9 | MBCProject_0108_T2_RNA | — | B | 0.849 |
| 10 | TCGA-49-4486-01A-01R-1206-07 | — | cohortA2 | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.620 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.430 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |